A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphomaXiaohong Han, Yuankai Shi, Qingyuan Zhang et al.|Chinese Journal of Cancer Research|2022Cited by 5
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 studyYuankai Shi, Yongping Song, Dong Wang et al.|BMC Cancer|2024Cited by 4